FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy-Reference-Cited by-同舟云学术

FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy

Published:2012-07-25 Issue:8 Volume:39 Page:650-656
ISSN:0305-1870
Container-title:Clinical and Experimental Pharmacology and Physiology
language:en
Short-container-title:Clin Exp Pharmacol Physiol

Author:

Tan Sih Min¹,Zhang Yuan¹,Wang Bing²,Tan Christina YR¹,Zammit Steven C³,Williams Spencer J³,Krum Henry²,Kelly Darren J

Affiliation:

1. The University of Melbourne; Department of Medicine; St Vincent's Hospital; Fitzory

2. Centre of Cardiovascular Research and Education in Therapeutics; Department of Epidemiology and Preventive Medicine; School of Public Health and Preventive Medicine; Monash University; Melbourne; Vic.; Australia

3. School of Chemistry; Bio21 Molecular Science and Biotechnology Institute; The University of Melbourne; Melbourne; Vic.; Australia

Publisher

Wiley

Subject

Physiology (medical),Pharmacology,Physiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1440-1681.2012.05726.x/fullpdf

Reference22 articles.

1. Diabetes mellitus and cardiac function;Mahgoub;Mol. Cell. Biochem.,1998

2. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy;Mifsud;Nephron Physiol.,2003

3. Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy;Kelly;Am. J. Physiol. Heart Circ. Physiol.,2007

4. The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: A double-blind, placebo-controlled trial;Holmes;Am. Heart J.,2000

5. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates;Zammit;Bioorg. Med. Chem. Lett.,2009

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy;Frontiers in Endocrinology;2024-07-30

2. Potential clinical biomarkers and perspectives in diabetic cardiomyopathy;Diabetology & Metabolic Syndrome;2023-03-04

3. The Role of Mitochondria in Metabolic Syndrome–Associated Cardiomyopathy;Oxidative Medicine and Cellular Longevity;2022-06-23

4. Metabonomic Characteristics of Myocardial Diastolic Dysfunction in Type 2 Diabetic Cardiomyopathy Patients;Frontiers in Physiology;2022-05-09

5. Role of novel biomarkers in diabetic cardiomyopathy;World Journal of Diabetes;2021-06-15